A

Business profile & competitive position

Agilent Technologies, Inc. (A) operates in the Healthcare sector, within the Medical - Diagnostics & Research industry. The company provides application-focused solutions for life sciences, diagnostics and applied markets, selling instruments, software, services and consumables that cover the entire laboratory workflow. Its customer base spans pharmaceutical, biotechnology, academic, government, environmental, food safety and clinical labs, which means revenue is delivered through a mix of large capital-equipment placements and recurring consumables and service contracts.

The reported profit metrics support the idea of a durable competitive position. A 19.5% net margin leaves nearly twenty cents of every revenue dollar as profit, while ROE of 20.5% is meaningfully higher than the low-to-mid-teen returns often seen across broader healthcare-equipment and industrial peers. Those figures are consistent with an installed-base business model, where replacement consumables, service contracts and proprietary workflows make switching costs meaningful. At the same time, a beta of 1.21 tells us the stock has historically been about 21% more volatile than the overall market, so the company is not a defensive hiding place despite the healthcare classification.

Financial posture

Agilent currently carries a market capitalization of $47.9 billion and trades on a P/E multiple of 33.4. That valuation multiple implies the market is pricing in continued above-average growth and margin durability, not a cheap, deep-value profile. Against a 19.5% net margin, the 33.4x P/E translates into an earnings yield of roughly 3.0%, meaning investors are accepting a low current earnings yield in exchange for expected earnings progression.

ROE of 20.5% is the standout efficiency metric in the provided data set. A return at that level generally indicates either superior asset turns, meaningful pricing power, or a leveraged equity structure that amplifies returns. With a beta of 1.21, Agilent also retains above-market sensitivity to macro shocks. At the current snapshot price of $169.89, the stock sits about 6.3% above its 50-day exponential moving average of $159.88, while the RSI of 56.0 is in neutral territory rather than an overbought or oversold extreme.

Strategic priorities & outlook

According to Agilent’s most recent 10-K filing, the company reorganized its reporting structure following a November 2024 realignment. It now reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The stated purpose of the reorganization is to support a market-focused, customer-centric strategy rather than a purely product-line structure.

The company lists three near-term operational priorities. First, it intends to expand the liquid chromatography application space with new columns, new services and ongoing enhancements to instruments and software. Second, it plans to continue improving its mass spectrometry portfolio, specifically targeting performance, sensitivity, precision, robustness, ease of use and onboard intelligence. Third, it aims to advance software and service solutions that help customers operate a digitally connected smart lab, leveraging data analytics, artificial intelligence and robotics.

Operationally, Agilent employed approximately 18,100 people worldwide as of October 31, 2025, including roughly 6,300 in Life Sciences and Diagnostics Markets, 7,400 in Agilent CrossLab and 2,500 in Applied Markets. Businesses are supported by centralized order fulfillment and supply-chain operations, referred to as OFS, plus a global infrastructure organization that provides shared services in finance, IT, legal, procurement, workplace and HR. Primary R&D and manufacturing sites are located in California, Colorado, Delaware, Massachusetts, Texas and Vermont in the United States, plus Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom. That global footprint provides scale but also embeds supply-chain and regulatory complexity across multiple jurisdictions.

Macro & geopolitical exposure

Because Agilent is classified under Medical - Diagnostics & Research, its exposures follow the structural realities of that industry rather than company-specific idiosyncrasies. Demand is tied to research-and-development budgets at pharmaceutical and biotechnology companies, government and academic research funding, hospital capital-expenditure cycles, and clinical laboratory activity. Any slowdown in biopharma funding or tightening in hospital lab budgets tends to translate into longer sales cycles for high-priced instruments.

Regulatory risk is inherent to the sector. Diagnostic products, clinical assays and related software are subject to clearance and enforcement by agencies such as the FDA in the United States and equivalent authorities in Europe, Japan and China. Reimbursement decisions by CMS and private payers also influence the economics of diagnostic testing. Supply chains for analytical instruments rely on specialized optical, electronic and chemical components sourced across North America, Europe and Asia, making the company sensitive to trade policy, tariffs, export controls and currency translation. China is a particularly important end market for laboratory tools, so shifts in Chinese academic or government spending can move the top line.

Recent developments

• October 13, 2026 — businesswire.com: Agilent announced an agreement to acquire Proscia, advancing AI-enabled digital pathology and scientific intelligence.
• October 12, 2026 — zacks.com: A headline asked whether Agilent Technologies (A) is outperforming other Medical stocks this year.
• October 2, 2026 — seekingalpha.com: Agilent was included in a dividend-contender highlight piece covering the week of October 4.
• October 1, 2026 — businesswire.com: Agilent introduced the NovoStation Sample Preparation System for automated flow cytometry workflows.

Viewed together, the two product or acquisition items fit the 10-K playbook. The Proscia deal is a direct extension of the smart-lab and AI-services priority, adding digital pathology capabilities to the broader scientific-data platform. The NovoStation launch addresses workflow automation, a recurring theme as labs look to reduce manual sample-prep steps. The Zacks and Seeking Alpha items remind investors that, in addition to growth execution, Agilent is also being evaluated against peer performance and its income credentials.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Agilent has beaten the official consensus six times, for an 86% beat rate, with an average earnings surprise of 3%. The average five-day price move following an earnings release has been +2.44%, classified as an “up” drift. That headline number, however, hides significant dispersion, and the data show that beating estimates does not guarantee a sustained move.

• August 26, 2026: Reported EPS of $1.62 versus an estimate of $1.49, an 8.7% positive surprise. The stock rose 1.68% the next day, but then fell 2.38% over the following five days.
• May 27, 2026: Reported EPS of $1.49 versus an estimate of $1.41, a 5.7% positive surprise. The stock jumped 16.87% the next day and extended the gain to 18.61% over five days.
• February 25, 2026: Reported EPS of $1.36 versus an estimate of $1.37, a 0.7% miss. The stock dropped 3.01% the next day and drifted another 3.35% lower over five days.
• November 24, 2025: Reported EPS of $1.59 versus an estimate of $1.58431, a 0.4% positive surprise. The stock gained 2.34% the next day but gave it back and more, falling 3.12% over five days.

The takeaway is that May 2026 was a clear beat-and-rally, while the more recent August 2026 beat and the November 2025 narrow beat both saw next-day enthusiasm reverse over the subsequent week. The February 2026 miss behaved in the more intuitive way: the stock sold off and kept drifting lower. The next scheduled release is November 23, 2026 after the close, with a current consensus EPS estimate of $1.72.

For traders and investors who want to go beyond these figures, the full institutional verdict offers additional detail on how sell-side analysts are modeling the November 23, 2026 report and what their expectations imply for the stock’s next move.